对《IGFBP7通过抑制甲状腺癌中的AKT活性和细胞周期进程来抑制细胞增殖》的更正
Correction to: IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma.
作者信息
Zhang Le, Lian Rong, Zhao Jingjing, Feng Xianming, Ye Runyi, Pan Lingxiao, Wu Jueheng, Li Mengfeng, Huang Yongbo, Cai Junchao
机构信息
1Key Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University, 74 Zhongshan Er Road, Guangzhou, 510080 Guangdong China.
2Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080 Guangdong China.
出版信息
Cell Biosci. 2019 Jul 15;9:57. doi: 10.1186/s13578-019-0319-6. eCollection 2019.
Abstract
[This corrects the article DOI: 10.1186/s13578-019-0310-2.].
摘要
[本文更正了文章的数字对象标识符：10.1186/s13578-019-0310-2。]
相似文献
1
Correction to: IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma.对《IGFBP7通过抑制甲状腺癌中的AKT活性和细胞周期进程来抑制细胞增殖》的更正
Cell Biosci. 2019 Jul 15;9:57. doi: 10.1186/s13578-019-0319-6. eCollection 2019.
2
IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma.胰岛素样生长因子结合蛋白7通过抑制甲状腺癌中的AKT活性和细胞周期进程来抑制细胞增殖。
Cell Biosci. 2019 Jun 6;9:44. doi: 10.1186/s13578-019-0310-2. eCollection 2019.
3
Correction: CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway.更正：CLCA4通过抑制PI3K/AKT信号通路来抑制膀胱癌细胞的增殖、迁移和侵袭。
Oncotarget. 2019 Jan 29;10(9):1010. doi: 10.18632/oncotarget.26656.
4
Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis.对《MicroRNA-214-3p通过靶向MELK抑制肝癌细胞增殖和细胞周期进程并与癌症预后相关》一文的更正
Cancer Cell Int. 2018 Apr 10;18:55. doi: 10.1186/s12935-018-0556-5. eCollection 2018.
5
IGFBP7: an oncosuppressor gene in thyroid carcinogenesis.IGFBP7：甲状腺癌发生中的抑癌基因。
Oncogene. 2010 Jul 1;29(26):3835-44. doi: 10.1038/onc.2010.136. Epub 2010 May 3.
6
IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma.IGFBP7 下调与肝细胞癌的肿瘤进展和临床结局相关。
Int J Cancer. 2012 Jan 15;130(2):319-27. doi: 10.1002/ijc.25994. Epub 2011 Apr 13.
7
IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma.IGFBP7 与预后相关，并能抑制胆管癌中的细胞存活。
Artif Cells Nanomed Biotechnol. 2018;46(sup2):817-825. doi: 10.1080/21691401.2018.1470524. Epub 2018 Jul 10.
8
Correction to: PML: Regulation and multifaceted function beyond tumor suppression.对《进行性多灶性白质脑病：肿瘤抑制之外的调控与多方面功能》的勘误
Cell Biosci. 2018 Mar 6;8:18. doi: 10.1186/s13578-018-0213-7. eCollection 2018.
9
Correction to: DNA mismatch repair in the context of chromatin.对《染色质背景下的DNA错配修复》的更正
Cell Biosci. 2020 Jul 2;10:84. doi: 10.1186/s13578-020-00447-7. eCollection 2020.
10
Erratum: miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways .勘误：miR-30d通过抑制MEK/ERK和PI3K/Akt信号通路抑制尤因肉瘤的细胞生物学进程。
Oncol Lett. 2021 Feb;21(2):133. doi: 10.3892/ol.2020.12394. Epub 2020 Dec 18.
本文引用的文献
1
IGFBP7 inhibits cell proliferation by suppressing AKT activity and cell cycle progression in thyroid carcinoma.胰岛素样生长因子结合蛋白7通过抑制甲状腺癌中的AKT活性和细胞周期进程来抑制细胞增殖。
Cell Biosci. 2019 Jun 6;9:44. doi: 10.1186/s13578-019-0310-2. eCollection 2019.
Zotero 插件